HER2 Support Group Forums - View Single Post - A Third (and New) Estrogen Receptor Is Discovered And Is Directly Tied To

Lani · 11-06-2006, 01:13 PM

In an effort to further refine the classification of GPR30, researchers in this study analyzed 361 tumor samples from breast cancer patients to compare the distribution patterns of standard estrogen receptors (ER) and GPR30. They examined how the various estrogen receptors associated with each other and their relationship with size of the primary breast tumor, lymph node invasion, and development of metastasis.

Results: showed that while the two types of receptors, GPR30 and the standard ERs, were commonly found together—their expression was not interdependent. This was best evidenced by the fact that approximately half of the ER-negative tumors remained positive for GPR30.

"This suggests that tumors traditionally viewed as being unreceptive to estrogen, may in fact, remain estrogen responsive," says co-author Edmond Sabo, MD, pathologist at Rhode Island Hospital and assistant professor at Brown Medical School. "If this is the case, it could significantly influence which patients are candidates for hormone therapy."

Researchers also found that GPR30 was positively associated with tumor size, and that primary tumors from patients with metastatic disease were twice as likely to express GPR30. Alternatively, an inverse relationship was measured between the standard estrogen receptors (ERa and ERb) and tumor size, and no significant association was found between receptor expression and the presence of metastatic disease.

11-06-2006, 01:13 PM	#2
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	More... In an effort to further refine the classification of GPR30, researchers in this study analyzed 361 tumor samples from breast cancer patients to compare the distribution patterns of standard estrogen receptors (ER) and GPR30. They examined how the various estrogen receptors associated with each other and their relationship with size of the primary breast tumor, lymph node invasion, and development of metastasis. Results: showed that while the two types of receptors, GPR30 and the standard ERs, were commonly found together—their expression was not interdependent. This was best evidenced by the fact that approximately half of the ER-negative tumors remained positive for GPR30. "This suggests that tumors traditionally viewed as being unreceptive to estrogen, may in fact, remain estrogen responsive," says co-author Edmond Sabo, MD, pathologist at Rhode Island Hospital and assistant professor at Brown Medical School. "If this is the case, it could significantly influence which patients are candidates for hormone therapy." Researchers also found that GPR30 was positively associated with tumor size, and that primary tumors from patients with metastatic disease were twice as likely to express GPR30. Alternatively, an inverse relationship was measured between the standard estrogen receptors (ERa and ERb) and tumor size, and no significant association was found between receptor expression and the presence of metastatic disease.